Patents by Inventor Joanne Wang

Joanne Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cells useful for immuno-based botulinum toxin serotype a activity assays
    Patent number: 8691566
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: April 8, 2014
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20140093957
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: December 28, 2011
    Publication date: April 3, 2014
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8663982
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: March 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8663983
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: March 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 8618261
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: Fernandez-Salas Ester, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Roger Aoki
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8603812
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8603813
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Immuno-Based Retargeted Endopeptidase Activity Assays
    Publication number: 20130267010
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Femandez-Salas
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20130236963
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: December 28, 2011
    Publication date: September 12, 2013
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8507271
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 13, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8501469
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 6, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8476068
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: July 2, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8476069
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: July 2, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 8455203
    Abstract: The present specification discloses SNAP-25 immune response inducing compositions, methods of making ?-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, ?-SNAP-25 antibodies that selectively bind to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, methods of detecting retargeted endopeptidase activity, and methods of detecting neutralizing ?-re-targeted endopeptidase antibodies.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Cells useful for immuno-based Botulinum toxin serotype A activity assays
    Patent number: 8455248
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8455247
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8455213
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20130040368
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: October 11, 2012
    Publication date: February 14, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina S. Wong, D. Dianne Hodges, Kei Roger Aoki
  • Cells useful for immuno-based Botulinum toxin serotype A activity assays
    Patent number: 8361789
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: January 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20120225436
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 6, 2012
    Applicant: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Diane Hodges, Kei Roger Aoki